# Bristol Myers Squibb Co: overview

BMY · NYSE · CIK 14272 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bmy.md) · [Financials](/companies/bmy/financials.md) · [Filings](/companies/bmy/filings.md) · [Insiders](/companies/bmy/insiders.md)

Latest reported revenue: [$12.97bn](/filings/0000014272-26-000020.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 30, 2026 (XBRL us-gaap:Revenues, accession 0000014272-26-000020).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [11.9](/filings/0000014272-25-000149.md) | [12.3 d](/filings/0000014272-26-000004.md) | [11.2](/filings/0000014272-26-000010.md) | [12.3](/filings/0000014272-26-000020.md) | [12.2](/filings/0000014272-25-000149.md) | [12.5 d](/filings/0000014272-26-000004.md) | [11.5](/filings/0000014272-26-000010.md) | [13.0](/filings/0000014272-26-000020.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [10.2%](/filings/0000014272-25-000149.md) | [0.6% d](/filings/0000014272-26-000004.md) | [21.9%](/filings/0000014272-26-000010.md) | [10.7%](/filings/0000014272-26-000020.md) | [18.0%](/filings/0000014272-25-000149.md) | [8.7% d](/filings/0000014272-26-000004.md) | [23.3%](/filings/0000014272-26-000010.md) | [25.6%](/filings/0000014272-26-000020.md) |
| Diluted EPS | $ per share | [0.60](/filings/0000014272-25-000149.md) | not reported | [1.20](/filings/0000014272-26-000010.md) | [0.64](/filings/0000014272-26-000020.md) | [1.08](/filings/0000014272-25-000149.md) | not reported | [1.31](/filings/0000014272-26-000010.md) | [1.62](/filings/0000014272-26-000020.md) |
| Free cash flow | $bn | [5.3 d](/filings/0000014272-25-000149.md) | [4.1 d](/filings/0000014272-26-000004.md) | [1.7](/filings/0000014272-26-000010.md) | [3.6 d](/filings/0000014272-26-000020.md) | [6.0 d](/filings/0000014272-25-000149.md) | [1.6 d](/filings/0000014272-26-000004.md) | [0.8](/filings/0000014272-26-000010.md) | [3.1 d](/filings/0000014272-26-000020.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [46.4](/filings/0000014272-24-000044.md) | [46.2](/filings/0000014272-25-000039.md) | [45.0](/filings/0000014272-26-000004.md) | [48.3](/filings/0000014272-26-000004.md) | [48.2](/filings/0000014272-26-000004.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [15.1%](/filings/0000014272-24-000044.md) | [13.7%](/filings/0000014272-25-000039.md) | [17.8%](/filings/0000014272-26-000004.md) | [(18.5%)](/filings/0000014272-26-000004.md) | [14.6%](/filings/0000014272-26-000004.md) |
| Diluted EPS | $ per share | [3.12](/filings/0000014272-24-000044.md) | [2.95](/filings/0000014272-25-000039.md) | [3.86](/filings/0000014272-26-000004.md) | [(4.41)](/filings/0000014272-26-000004.md) | [3.46](/filings/0000014272-26-000004.md) |
| Free cash flow | $bn | [15.2](/filings/0000014272-24-000044.md) | [11.9](/filings/0000014272-25-000039.md) | [12.7](/filings/0000014272-26-000004.md) | [13.9](/filings/0000014272-26-000004.md) | [12.8](/filings/0000014272-26-000004.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bmy/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $10.39bn | 180,384,994 |  | Added +8,702,106 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $7.68bn | 133,337,856 |  | Added +1,017,616 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $5.90bn | 102,408,940 |  | Added +3,844,026 |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $4.20bn | 71,713,442 |  | Reduced −20,761,752 |
| [CHARLES SCHWAB INVESTMENT MANAGEMENT INC](/funds/884546.md) | 2026-06-30 | $3.89bn | 67,595,177 |  | Added +6,479,804 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $3.24bn | 56,443,077 |  | Added +1,156,903 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $2.70bn | 46,873,015 |  | Added +642,860 |
| [NORGES BANK](/funds/1374170.md) | 2026-06-30 | $2.12bn | 36,866,658 |  | New +36,866,658 |
| [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $1.96bn | 34,045,352 |  | Added +1,458,371 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $1.67bn | 29,009,025 |  | Reduced −189,529 |

## Recent filings

[All 2,590 filings](/companies/bmy/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 07:05 ET | [8-K](/filings/0000014272-26-000022.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000014272-26-000022 |
| 2026-07-30 | 11:10 ET | [10-Q](/filings/0000014272-26-000020.md) | Quarterly report, period 2026-06-30 | 0000014272-26-000020 |
| 2026-07-30 | 07:05 ET | [8-K](/filings/0000014272-26-000018.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000014272-26-000018 |
| 2026-05-08 | 16:10 ET | [8-K](/filings/0001140361-26-020036.md) | 5.07 Shareholder vote results | 0001140361-26-020036 |
| 2026-04-30 | 11:44 ET | [10-Q](/filings/0000014272-26-000010.md) | Quarterly report, period 2026-03-31 | 0000014272-26-000010 |
| 2026-04-30 | 07:01 ET | [8-K](/filings/0000014272-26-000008.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000014272-26-000008 |
| 2026-03-25 | 16:19 ET | [DEF 14A](/filings/0000014272-26-000006.md) | Proxy statement, period 2026-05-05 | 0000014272-26-000006 |
| 2026-02-11 | 11:35 ET | [10-K](/filings/0000014272-26-000004.md) | Annual report, period 2025-12-31 | 0000014272-26-000004 |
| 2026-02-05 | 07:07 ET | [8-K](/filings/0000014272-26-000002.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000014272-26-000002 |
| 2026-01-12 | 10:20 ET | [8-K](/filings/0001140361-26-000929.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-000929 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0000014272-26-000004.md), filed Feb 11, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, locked when the 8-K was accepted. It is scored when the 10-Q or 10-K is ingested. [See the target](/leagues/2026q3/targets/13179f3c-117d-4a39-b4cb-ab165e9f9e6d)

## About the filer

- CIK: 14272
- Tickers: BMY, CELG-RI
- Exchange: NYSE
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 11:17 ET. No prices; not investment advice.